Graham R Foster
Affiliation: Imperial College
- Hepatitis C virus infection: quality of life and side effects of treatmentG R Foster
The Liver Unit, Imperial College of Medicine at St Mary s, St Mary s Hospital, London, UK
J Hepatol 31:250-4. 1999....
- Past, present, and future hepatitis C treatmentsGraham R Foster
Hepatobiliary Group, Department of Adult and Paediatric Gastroenterology, Queen Marys School of Medicine and Dentistry, London, United Kingdom
Semin Liver Dis 24:97-104. 2004....
- Directed evolution of gene-shuffled IFN-alpha molecules with activity profiles tailored for treatment of chronic viral diseasesAmy D Brideau-Andersen
Maxygen, Incorporated, 515 Galveston Drive, Redwood City, CA 94063, USA
Proc Natl Acad Sci U S A 104:8269-74. 2007....
- Therapeutic options for HCV--management of the infected individualG R Foster
The Liver Centre, Imperial College School of Medicine at St Mary s Hospital, London, UK
Baillieres Best Pract Res Clin Gastroenterol 14:255-64. 2000..New therapies including polyethylene glycol, PEGylated, interferons and combination regimes involving amantadine are currently under evaluation and it is hoped that improved regimes will be developed in the near future...
- Human T cells elicit IFN-alpha secretion from dendritic cells following cell to cell interactionsG R Foster
Department of Medicine, ICSM, St Mary s Hospital, London, GB
Eur J Immunol 30:3228-35. 2000..Type I DC produce Type I IFN not only following viral infection but also during an immunological interaction and this may be the basic mechanism that assists in the development of a Th1 response...
- Management of chronic hepatitis C--time for a change?Graham R Foster
Imperial College Faculty of Medicine at St Mary s, St Mary s Hospital, Praed Street, London W2 1PG, UK
J Viral Hepat 9:82-3. 2002
- Pegylated interferons for the treatment of chronic hepatitis C: pharmacological and clinical differences between peginterferon-alpha-2a and peginterferon-alpha-2bGraham R Foster
Queen Mary University of London, The Liver Unit, Blizard Institute of Cellular and Molecular Science, Barts and the London School of Medicine, The Royal London Hospital, London, UK
Drugs 70:147-65. 2010..Peginterferon plus ribavirin, as the standard of care for patients with chronic hepatitis C, may in the future form the basis of improved treatment regimens that include new, targeted anti-HCV agents to increase SVR rates even further...
- Prediction of sustained virological response in chronic hepatitis C patients treated with peginterferon alfa-2a (40KD) and ribavirinGraham R Foster
The Royal London Hospital, London, UK
Scand J Gastroenterol 42:247-55. 2007..The purpose of this study was to model the probability of achieving a sustained virological response in individual patients, taking into consideration various predictive factors...
- Telaprevir alone or with peginterferon and ribavirin reduces HCV RNA in patients with chronic genotype 2 but not genotype 3 infectionsGraham R Foster
Queen Marys University of London, Blizard Institute of Cellular and Molecular Science, London, UK
Gastroenterology 141:881-889.e1. 2011..We evaluated antiviral activity of 2 weeks therapy with telaprevir alone, peginterferon alfa-2a and ribavirin (PR), or all 3 drugs (TPR) in treatment-naïve patients with chronic hepatitis C virus (HCV) genotype 2 or 3 infections...
- Sustained virologic response rates with telaprevir by response after 4 weeks of lead-in therapy in patients with prior treatment failureGraham R Foster
Queen Marys University of London, Institute of Cell and Molecular Science, London, UK
J Hepatol 58:488-94. 2013....
- Response to antiviral therapy in patients with genotype 3 chronic hepatitis C: fibrosis but not race encourages relapseDania Shoeb
The Liver Unit, Blizard Institute for Cellular and Molecular Science, Queen Mary University of London, London, UK
Eur J Gastroenterol Hepatol 23:747-53. 2011..We completed a retrospective analysis of patients with genotype 3 hepatitis C virus (HCV) undergoing therapy in four UK centres with large populations of patients from the Indian subcontinent...
- Pegylated interferon with ribavirin therapy for chronic infection with the hepatitis C virusGraham R Foster
Department of Adult and Paediatric Gastroenterology, The Royal London Hospital, Turner Street, London, E1 2AD, UK
Expert Opin Pharmacother 4:685-91. 2003..Their ease of administration, coupled with their improved efficacy, is likely to lead to an increase in the proportion of infected patients who wish to receive treatment...
- Randomized clinical trial: a pilot study investigating the safety and effectiveness of an escalating dose of peginterferon α-2a monotherapy for 48 weeks compared with standard clinical care in patients with hepatitis C cirrhosisSudeep Tanwar
Department of Medicine, Centre for Hepatology, University College London, London, UK
Eur J Gastroenterol Hepatol 24:543-50. 2012....
- Triple combination treatment for chronic hepatitis C with protease inhibitors, pegylated interferon and ribavirin: 'lead-in or no lead-in'?Graham R Foster
Department of Hepatology, Queen Mary, University of London, London, UK
Liver Int 32:61-3. 2012..Those opposed to the 'lead-in' phase cite the complexity of the regime and the lack of robust evidence showing an improvement in clinical outcome in those treated in this fashion...
- Hepatitis C virus treatment for prevention among people who inject drugs: Modeling treatment scale-up in the age of direct-acting antiviralsNatasha K Martin
School of Social and Community Medicine, University of Bristol, Bristol, UK Social and Mathematical Epidemiology Group, Department of Global Health and Development, London School of Hygiene and Tropical Medicine, London, UK
Hepatology 58:1598-609. 2013..At existing HCV drug costs, halving chronic prevalence would require annual treatment budgets of US $3.2 million in Edinburgh and approximately $50 million in Melbourne and Vancouver...
- A randomized, controlled study of peginterferon lambda-1a/ribavirin ± daclatasvir for hepatitis C virus genotype 2 or 3Graham R Foster
Department of Hepatology, Queen Mary University of London, 4 Newark Street, London, UK
Springerplus 5:1365. 2016....
- Ethnicity and the diagnosis gap in liver disease: a population-based studyWilliam Alazawi
The Liver Unit, The Blizard Institute, Barts and the London School of Medicine, London, UK
Br J Gen Pract 64:e694-702. 2014..Non-alcoholic fatty liver disease (NAFLD) is the most common cause of chronic liver injury. Metabolic syndrome, common in people from South Asia, is an important risk factor for NAFLD...
- Development and validation of a "capture-fusion" model to study drug sensitivity of patient-derived hepatitis CMorven E Cunningham
The Liver Unit, Blizard Institute, Queen Mary University of London, London, United Kingdom
Hepatology 61:1192-204. 2015..We studied samples from a 2-week TVR monotherapy study in which 5 of 8 patients with G3 HCV did not respond whereas 3 of 8 patients did. The "capture-fusion" assay correctly identified responders...
- Endothelin-1 as a mediator and potential biomarker for interferon induced pulmonary toxicityPeter M George
Cardiothoracic Pharmacology, National Heart and Lung Institute, Imperial College, London, UK
Pulm Circ 2:501-4. 2012..This hypothesis can be easily tested in IFN-treated patients by measuring serum endothelin-1 levels and cardiopulmonary physiological parameters...
- Hepatitis C prevalence in England remains low and varies by ethnicity: an updated evidence synthesisRoss J Harris
Health Protection Agency Centre for Infections, London, UK
Eur J Public Health 22:187-92. 2012..We incorporate new information on HCV risk among non-injectors by ethnic group, and additional information on injecting prevalence in order to generate new and updated estimates of HCV prevalence risk in England for 2005...
- Managing diabetes in patients with chronic liver diseaseRoaid Khan
Department of Diabetes and Metabolism, The Royal London Hospital, London, UK
Postgrad Med 124:130-7. 2012..Management of patients with diabetes and CLD may be enhanced by using a multidisciplinary approach...
- Diagnosis and treatment of chronic hepatitis BRaymond D'Souza
Digestive Disease Research Centre, Queen Mary s School of Medicine and Dentistry, Barts and The London NHS Trust, London, UK
J R Soc Med 97:318-21. 2004
- Advances in the diagnosis and treatment of hepatitis BWilliam Alazawi
The Liver Unit, Barts and the London School of Medicine, London, UK
Curr Opin Infect Dis 21:508-15. 2008..Although the armament of drugs licensed for its treatment grows, it is increasingly apparent that the efficacy of these drugs is dependent upon much more that their pharmacology...
- Hepatitis C and cognitive impairment in a cohort of patients with mild liver diseaseDaniel M Forton
Hepatology Section, Division of Medicine A, Faculty of Medicine, Imperial College, St Mary s Hospital, London, UK
Hepatology 35:433-9. 2002..The findings on MRS suggest that a biological cause underlies this abnormality...
- Diagnosis and treatment of hepatitis CRaymond D'Souza
Digestive Disease Research Centre, Royal London Hospital, Turner Street, London E1 1BB, UK
J R Soc Med 97:223-5. 2004
- Health-related quality of life before, during and after combination therapy with interferon and ribavirin in unselected Swedish patients with chronic hepatitis CAnna Hollander
Division of Infectious Diseases, Department of Medicine, Karolinska Institutet at Karolinska University Hospital Huddinge, Stockholm, Sweden
Scand J Gastroenterol 41:577-85. 2006..To study the relationship between health-related quality of life (HRQOL) and mode of acquisition, treatment discontinuations, drop in haemoglobin levels and treatment outcome in patients with chronic hepatitis C (CHC)...
- The way forward in HCV treatment--finding the right pathMichael P Manns
Department of Gastroenterology, Hepatology and Endocrinology, Medical School of Hannover, Hannover, Germany
Nat Rev Drug Discov 6:991-1000. 2007..Here we review the specific challenges posed by HCV, and recent developments in the design of vaccines and novel antiviral agents...
- Activity of hybrid type I interferons in cells lacking Tyk2: a common region of IFN-alpha 8 induces a response, but IFN-alpha2/8 hybrids can behave like IFN-betaDimitris Platis
Imperial College Faculty of Medicine at St Mary s Hospital, London W2 1NY, England
J Interferon Cytokine Res 23:655-66. 2003..This suggests that this hybrid mimics the interactions of IFN-beta with the receptor and also suggests the existence of a distinct binding site(s) on IFNAR for IFN-beta and some hybrid IFN-alphas...
- Combination therapy with amantadine and interferon in naïve patients with chronic hepatitis C: meta-analysis of individual patient data from six clinical trialsAlessandra Mangia
Division of Gastroenterology, Ospedale Casa Sollievo Sofferenza, IRCCS, San Giovanni Rotondo 71013, Italy
J Hepatol 40:478-83. 2004..We performed a meta-analysis of the individual patient's data from previous studies...
- IFN-alpha subtypes differentially affect human T cell motilityGraham R Foster
Hepatobiliary Group, Department of Gastroenterology, Queen Mary s School of Medicine and Dentistry at Barts and The Royal London Hospital, United Kingdom
J Immunol 173:1663-70. 2004..These observations are consistent with the possibility that subtype-specific intracellular signaling pathways are activated by type I IFNs in T lymphocytes...
- Dengue virus inhibits alpha interferon signaling by reducing STAT2 expressionMeleri Jones
DDRC, Queen Mary s School of Medicine and Dentistry, Royal Free and University College Medical School, Rowland Hill St, London NW3 2PF, United Kingdom
J Virol 79:5414-20. 2005..Collectively, these data show that dengue virus is capable of subverting the human IFN response by down-regulating STAT2 expression...
- Prevalence of hepatitis C-related cirrhosis in elderly Asian patients infected in childhoodRaymond D'Souza
Hepatobiliary Group, Department of Adult and Pediatric Gastroenterology, Barts and The London, Queen Mary s School of Medicine and Dentistry, London, United Kingdom
Clin Gastroenterol Hepatol 3:910-7. 2005....
- Chronic exposure to Helicobacter pylori impairs dendritic cell function and inhibits Th1 developmentPeter Mitchell
Department of Immunology, Division of Medicine, Faculty of Medicine, Imperial College at Hammersmith Hospital, London, United Kingdom
Infect Immun 75:810-9. 2007..Our results raise the possibility that in chronic H. pylori infection DCs become exhausted after prolonged antigen exposure leading to suboptimal Th1 development. This effect may contribute to persistence of H. pylori infection...
- Interferons at age 50: past, current and future impact on biomedicineErnest C Borden
Taussig Cancer Center, Case Comprehensive Cancer Center, Mellen Center for Multiple Sclerosis, and Lerner Research Institute, The Cleveland Clinic, 9500 Euclid Avenue, Cleveland, Ohio 44195, USA
Nat Rev Drug Discov 6:975-90. 2007..Our goal is to offer a molecular and clinical perspective that will enable IFNs or their TLR agonist inducers to reach their full clinical potential...
- High yield expression, refolding, and characterization of recombinant interferon alpha2/alpha8 hybrids in Escherichia coliDimitris Platis
Imperial College Faculty of Medicine at St Mary s Hospital, South Wharf Road, London W2 1NY, UK
Protein Expr Purif 31:222-30. 2003....